Skip to content

Jefferies updates its list of highest-conviction Buy-rated stocks

Jefferies updates its list of highest-conviction Buy-rated stocks
Marko
Stocks

Jefferies, an investment banking and capital management firm, has updated its ‘Franchise Picks’ list, which features the company’s highest-conviction ‘Buy’ rated stocks.

The reshuffling shows a clear preference for U.S. equities with ties to artificial intelligence (AI) infrastructure, digital advertising, healthcare, and selective consumer value opportunities.

Most notably, the research team added new positions in Amazon (NASDAQ: AMZN), AppLovin (NASDAQ: APP), and Credo Technology (NASDAQ: CRDO).

Other notable additions include McDonald’s (NYSE: MCD) , Thermo Fisher (NYSE: TMO), American Healthcare REIT (NYSE: AHR), and Ovintiv (NYSE: OVV).

Jefferies removes Broadcom and Nike from its ‘Franchise Picks’

At the same time, the firm removed some rather notable names from the list, including American International Group (NYSE: AIG), Broadcom (NASDAQ: AVGO), and Nike(NYSE: NSE).

Elaborating on the updates, Jefferies said the new lineup is indeed a step further toward AI-driven infrastructure and monetization themes, alongside defensive and steady-growth exposure in healthcare and consumer staples.

The bank highlighted Amazon as benefiting from early-stage reacceleration in Amazon Web Services (AWS), as new capacity comes online and AI partnerships strengthen long-term revenue visibility. 

Similarly, AppLovin was added for its position in mobile gaming advertising and expanding direct-to-consumer e-commerce exposure, while Credo made the cut on expectations of increased adoption of active electrical cable technology.

On the consumer side, McDonald’s illustrates the company’s hope that McValue platform can support same-store sales and help defend market share, even amid subdued near-term expectations.

Jefferies’ favorite healthcare stocks

In healthcare, RadNet (NASDAQ: RDNT) was cited for rising outpatient imaging demand, including growth in PET, MRI, and CT procedures. At the same time, Thermo Fisher was added on expectations of an earnings inflection tied to improving biopharma demand in the second half of the year.

Further, UL Solutions (NYSE: ULS) was highlighted for its leadership in testing, inspection, and certification services, with Jefferies pointing to pricing power, macro resilience, and potential upside from AI-related testing demand.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD
Finbold Career

Join Finbold's newsroom, become a Sales Executive today!

Apply now to join Finbold as a crypto/finance news writer!

Latest posts

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.